Literature DB >> 1371219

Isoform-selective deficit of glycine receptors in the mouse mutant spastic.

C M Becker1, V Schmieden, P Tarroni, U Strasser, H Betz.   

Abstract

The mutant mouse spastic (spa) develops a characteristic motor disorder about 2 weeks after birth, with symptoms resembling sublethal poisoning by the glycinergic antagonist strychnine. Correspondingly, adult homozygotic mutants (spa/spa) exhibit a severe reduction of inhibitory glycine receptors in spinal cord and brain. Here we show that the spastic mutation selectively interferes with the postnatal accumulation of the adult isoform of the glycine receptor protein, whereas perinatal expression of the neonatal receptor isoform is not detectably affected. Heterologous expression in X. laevis oocytes of poly(A)+ RNA and Northern blot analysis indicate normal levels of glycine receptor alpha 1 subunit transcripts in spinal cord of adult spastic mutants. Thus, the age-dependent manifestation of spastic symptoms after birth reflects a selective effect of the mutation on the developmental expression of the adult glycine receptor isoform.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371219     DOI: 10.1016/0896-6273(92)90295-o

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  24 in total

Review 1.  Modulating inhibitory ligand-gated ion channels.

Authors:  Michael Cascio
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

2.  Homology modeling and molecular dynamics simulations of the glycine receptor ligand binding domain.

Authors:  Kirill Speranskiy; Michael Cascio; Maria Kurnikova
Journal:  Proteins       Date:  2007-06-01

3.  A GLRA1 null mutation in recessive hyperekplexia challenges the functional role of glycine receptors.

Authors:  W Brune; R G Weber; B Saul; M von Knebel Doeberitz; C Grond-Ginsbach; K Kellerman; H M Meinck; C M Becker
Journal:  Am J Hum Genet       Date:  1996-05       Impact factor: 11.025

Review 4.  GABA(A) receptor and glycine receptor activation by paracrine/autocrine release of endogenous agonists: more than a simple communication pathway.

Authors:  Herve Le-Corronc; Jean-Michel Rigo; Pascal Branchereau; Pascal Legendre
Journal:  Mol Neurobiol       Date:  2011-05-06       Impact factor: 5.590

5.  Zebrafish bandoneon mutants display behavioral defects due to a mutation in the glycine receptor beta-subunit.

Authors:  Hiromi Hirata; Louis Saint-Amant; Gerald B Downes; Wilson W Cui; Weibin Zhou; Michael Granato; John Y Kuwada
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-31       Impact factor: 11.205

6.  Disease-specific human glycine receptor alpha1 subunit causes hyperekplexia phenotype and impaired glycine- and GABA(A)-receptor transmission in transgenic mice.

Authors:  Lore Becker; Jörg von Wegerer; Johannes Schenkel; Hanns-Ulrich Zeilhofer; Dieter Swandulla; Hans Weiher
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

7.  The glycinergic system in human startle disease: a genetic screening approach.

Authors:  Jeff S Davies; Seo-Kyung Chung; Rhys H Thomas; Angela Robinson; Carrie L Hammond; Jonathan G L Mullins; Eloisa Carta; Brian R Pearce; Kirsten Harvey; Robert J Harvey; Mark I Rees
Journal:  Front Mol Neurosci       Date:  2010-03-23       Impact factor: 5.639

8.  Defective glycinergic synaptic transmission in zebrafish motility mutants.

Authors:  Hiromi Hirata; Eloisa Carta; Iori Yamanaka; Robert J Harvey; John Y Kuwada
Journal:  Front Mol Neurosci       Date:  2010-01-08       Impact factor: 5.639

9.  Glycine receptor-mediated synaptic transmission regulates the maturation of ganglion cell synaptic connectivity.

Authors:  Hong-Ping Xu; Ning Tian
Journal:  J Comp Neurol       Date:  2008-07-01       Impact factor: 3.215

10.  Low level expression of glycine receptor beta subunit transgene is sufficient for phenotype correction in spastic mice.

Authors:  B Hartenstein; J Schenkel; J Kuhse; B Besenbeck; C Kling; C M Becker; H Betz; H Weiher
Journal:  EMBO J       Date:  1996-03-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.